Background/aims: Patients with chronic kidney disease (CKD) have been found to show markedly increased rates of end-stage renal disease, major adverse cardiovascular and cerebrovascular events (MACCEs), and mortality. Therefore, new biomarkers are required for the early detection of such clinical outcomes in patients with CKD. We aimed to determine whether the level of circulating renalase was associated with CKD progression, MACCEs, and all-cause mortality, using data from a prospective randomized controlled study, Kremezin STudy Against Renal disease progression in Korea (K-STAR; NCT00860431).

Methods: A retrospective analysis of the K-STAR data was performed including 383 patients with CKD (mean age, 56.4 years; male/female, 252/131). We measured circulating renalase levels and examined the effects of these levels on clinical outcomes.

Results: The mean level of serum renalase was 75.8 ± 34.8 μg/mL. In the multivariable analysis, lower hemoglobin levels, higher serum creatinine levels, and diabetes mellitus were significantly associated with a higher renalase levels. Over the course of a mean follow-up period of 56 months, 25 deaths and 61 MACCEs occurred. Among 322 patients in whom these outcomes were assessed, 137 adverse renal outcomes occurred after a mean follow-up period of 27.8 months. Each 10- μg/mL increase in serum renalase was associated with significantly greater hazards of all-cause mortality and adverse renal outcomes (hazard ratio [HR] = 1.112, p = 0.049; HR = 1.052, p = 0.045). However, serum renalase level was not associated with the rate of MACCEs in patients with CKD.

Conclusion: Our results indicated that circulating renalase might be a predictor of mortality and adverse renal outcomes in patients with CKD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610203PMC
http://dx.doi.org/10.3904/kjim.2017.058DOI Listing

Publication Analysis

Top Keywords

circulating renalase
16
renal outcomes
16
all-cause mortality
12
outcomes patients
12
patients ckd
12
serum renalase
12
adverse renal
12
chronic kidney
8
kidney disease
8
renal disease
8

Similar Publications

The early diagnostic value of serum renalase level in diabetic kidney disease and diabetic macroangiopathy: a retrospective case-control study.

Ther Adv Chronic Dis

October 2024

Shanghai Diabetes Institute, Shanghai Key Clinical Center for Metabolic Diseases, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China.

Background: Diabetic kidney disease (DKD) is a severe complication of diabetes mellitus and is associated with an increased risk of end-stage renal disease (ESRD) and cardiovascular events. Early diagnosis and monitoring of DKD are crucial for implementing appropriate interventions. This study aimed to investigate the relationship between serum renalase (RNLS) levels, DKD, and diabetic macroangiopathy in patients with type 2 diabetes mellitus (T2DM).

View Article and Find Full Text PDF
Article Synopsis
  • SGLT2 inhibitors like sotagliflozin show promise in improving health status for heart failure patients, but effects of SGLT1/SGLT2 inhibition remain unclear.* -
  • In the SOLOIST-WHF trial, patients taking sotagliflozin after a heart failure episode experienced a significant improvement in their Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) scores compared to those on placebo.* -
  • Overall, sotagliflozin not only reduced hospitalizations and cardiovascular deaths but also led to improved symptoms and quality of life within four months, benefiting patients regardless of their left ventricular ejection fraction.*
View Article and Find Full Text PDF

Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial.

Nephrol Dial Transplant

December 2024

Department of Medicine, Division of Nephrology, University Health Network, Toronto, Ontario, Canada.

Background: Volenrelaxin is a half-life-extended recombinant human relaxin protein developed for improving kidney perfusion and cardiorenal function. This study assessed the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of volenrelaxin following single- and multiple-ascending doses (SAD and MAD) administration.

Methods: In this Phase 1, four-part, randomized, double-blinded, placebo-controlled SAD and MAD study in healthy participants, SAD participants (n = 56) received an intravenous or subcutaneous dose of volenrelaxin or placebo in a dose-ascending manner.

View Article and Find Full Text PDF

A potential antifibrotic mechanism in pathological myocardial remodeling is the recruitment of beneficial functional subpopulations of macrophages or the transformation of their phenotype. Macrophages are required to activate molecular cascades that regulate fibroblast behavior. Identifying mediators that activate the antifibrotic macrophage phenotype is tantamount to identifying the button that retards pathological remodeling of the myocardium; however, relevant studies are inadequate.

View Article and Find Full Text PDF

Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF.

JACC Heart Fail

August 2023

Université Paris-Cité, Institut Universitaire de France, INSERM U-1148, FACT (French Alliance for Cardiovascular Trials) and AP-HP (Assistance Publique-Hôpitaux de Paris), Hopital Bichat Paris, Paris, France.

Article Synopsis
  • Around 25% of patients with worsening heart failure (WHF) are readmitted to hospitals within 30 days after discharge.
  • The SOLOIST-WHF trial analyzed the effects of the drug sotagliflozin compared to a placebo on reducing heart failure-related deaths and events for patients who started treatment before leaving the hospital.
  • Results showed that starting sotagliflozin at discharge significantly lowered the risk of cardiovascular deaths and heart failure events at both 30 and 90 days, indicating its potential benefits for patients with type 2 diabetes post-hospitalization.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!